---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-046136"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2021-08-27T23:59:59+00:00"
generated_at: "2026-06-29T07:23:06.324334+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Director Graham Walmsley resigns from ALX Oncology board effective Aug 26, 2021

## Summary
- Graham Walmsley resigned due to professional responsibilities at Logos Global Management, not due to any disagreement.
- Board size reduced from seven to six directors.
- Jason Lettmann appointed to the Audit Committee following the resignation.

## SEC filing metadata
- accession: 0001564590-21-046136
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2021-08-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000156459021046136/0001564590-21-046136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000156459021046136/alxo-8k_20210826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-046136
- JSON: https://secwatch.observer/filing/0001564590-21-046136.json
- Plain text: https://secwatch.observer/filing/0001564590-21-046136.txt

## Key facts
- Executive change
  Graham Walmsley resigned as director at ALX ONCOLOGY HOLDINGS INC.
  - Action: resigned
  - Role: director
  source text: On August 26, 2021, Graham Walmsley, M.D., Ph.D., informed the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) that he would resign from the Board effective August 26, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000156459021046136/0001564590-21-046136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.